First blood biomarker developed in Catalonia to predict progression from mild cognitive impairment to Alzheimer’s dementia
IDIBELL and the Bellvitge University Hospital have played a key role in the clinical validation of a new blood biomarker discovered and developed in Catalonia which, for the first time, makes it possible to predict the progression from mild cognitive impairment (MCI) to Alzheimer’s dementia. While recently developed international blood biomarkers can confirm the presence










